The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$217.74 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:-

Congenital hyperinsulinism is a rare genetic disorder caused by excessive insulin secretion from the pancreas leading to hypoglycemia. The standard treatment includes drug therapy such as diazoxide and octreotide as first-line treatment options, while surgery in severe cases of disease which is not responsive to medications. Novel therapeutics represent a promising area for research and development to improve treatment outcomes in patients with congenital hyperinsulinism.

Market key trends:-

One of the key trends in the congenital hyperinsulinism treatment market is the rising focus on developing novel therapeutic options with improved efficacy and safety profiles. Drug development in this space is currently focused on next-generation small molecule inhibitors of glucokinase and sulfonylurea receptors. Additionally, gene therapy is also emerging as a novel treatment approach wherein modified genes are introduced into patients’ cells and tissues to treat congenital hyperinsulinism at its genetic roots. Such novel therapies have the potential to overcome limitations of existing treatment modalities and thereby drive the market growth over the forecast period.

Segment Analysis:-

The global congenital hyperinsulinism treatment market is segmented into drug class, distribution channel, and region. Based on drug class, the market is classified into long-acting diazoxide, imidazole derivative diazoxide, and others. The long-acting diazoxide segment is expected to dominate the market during the forecast period due to its long-lasting and effective properties compared to conventional diazoxide.

Key Takeaways:-

The global congenital hyperinsulinism treatment market is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing awareness about rare diseases and advancements in treatment options.

Regional analysis:-

North America is expected to dominate the global congenital hyperinsulinism treatment market during the forecast period. This is attributed to presence of advanced healthcare facilities, increasing research & development activities, and rising awareness about rare diseases in the region. Asia Pacific is anticipated to witness fastest growth rate over the forecast period, owing to growing healthcare expenditure and improving healthcare infrastructure in emerging economies like China and India.

Key players:-

Key players operating in the congenital hyperinsulinism treatment market are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd. Zealand Pharma recently received FDA approval for glepaglutide, a long acting GLP-1 analog, to treat CHI.

*Note:
1.  Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it